Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study

BACKGROUND: In the phase 3 RADIANT-2 study, everolimus plus octreotide long-acting repeatable (LAR) showed improvement of 5.1 months in median progression-free survival versus placebo plus octreotide LAR among patients with advanced neuroendocrine tumors associated with carcinoid syndrome. The progr...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Ann Oncol
Asıl Yazarlar: Pavel, M.E., Baudin, E., Öberg, K.E., Hainsworth, J.D., Voi, M., Rouyrre, N., Peeters, M., Gross, D.J., Yao, J.C.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2017
Konular:
Gastrointestinal tumor
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7360141/
https://ncbi.nlm.nih.gov/pubmed/28444114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdx193
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller